Weiqi Zhang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Weiqi Zhang has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
Haocheng Wang
Department of Gastrointestinal Surgery, Zhujiang Hospital, Southern Medical University, GuangZhou, China
1 shared publicationHaopeng Liu
1 shared publicationJiale Liu
Guangdong Provincial Biomedical Engineering Technology Research Center for Cardiovascular Disease, Zhujiang Hospital, Southern Medical University, Guangzhou, China
1 shared publication- Jie Zhan
Nanfang Hospital, Southern Medical University
1 shared publication Jingyue Pan
1 shared publicationNing Liao
1 shared publication
Latest Publications
- Open Access
- 3 October 2026
- Published by Elsevier in SSRN Electronic Journal
Antibody-Peptide Assembly Conjugates Coordinate TREM2 and PD-1 Blockade for Macrophage-Centred Antitumour Immunity in Triple-Negative Breast Cancer
Immunosuppressive tumour-associated macrophages (TAMs) constrain the efficacy of immunotherapy in triple-negative breast cancer (TNBC), yet therapeutic systems that concurrently disrupt complementary macrophage-centred checkpoints remain scarce. Here we report antibody-peptide assembly conjugates (APACs), which integrate an anti-TREM2 antibody with a self-assembling PD-1-blocking peptide within a single supramolecular construct. Integrated bulk, single-cell and spatial analyses of human breast tumours identified partially overlapping TREM2- and PD-1-expressing macrophage populations and a TREM2/PDCD1-associated TAM state characterized by immunoregulatory signalling, lipid-metabolic adaptation and attenuated phagocytic and antigen-processing programmes. Appending a phenylalanine-containing assembly motif to the PD-1-blocking peptide promoted the formation of β-sheet-enriched nanofibres, and this peptide-driven assembly behaviour was retained after bioorthogonal conjugation to the anti-TREM2 antibody. APACs redirected TAMs from lipid-supported oxidative respiration towards glycolysis, enhanced tumour-cell phagocytosis and antigen-specific CD8⁺ T-cell activation, and produced sustained, macrophage-dependent tumour control and reduced pulmonary and hepatic metastatic burden in syngeneic TNBC models. These findings establish a biologically guided supramolecular strategy that integrates TREM2-directed macrophage modulation with PD-1 blockade to coordinate innate and adaptive antitumour immunity within macrophage-rich TNBC niches.
- 3 October 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessAntibody-Peptide Assembly Conjugates Coordinate TREM2 and PD-1 Blockade for Macrophage-Centred Antitumour Immunity in Triple-Negative Breast Cancer
Immunosuppressive tumour-associated macrophages (TAMs) constrain the efficacy of immunotherapy in triple-negative breast cancer (TNBC), yet therapeutic systems that concurrently disrupt complementary macrophage-centred checkpoints remain scarce. Here we report antibody-peptide assembly conjugates (APACs), which integrate an anti-TREM2 antibody with a self-assembling PD-1-blocking peptide within a single supramolecular construct. Integrated bulk, single-cell and spatial analyses of human breast tumours identified partially overlapping TREM2- and PD-1-expressing macrophage populations and a TREM2/PDCD1-associated TAM state characterized by immunoregulatory signalling, lipid-metabolic adaptation and attenuated phagocytic and antigen-processing programmes. Appending a phenylalanine-containing assembly motif to the PD-1-blocking peptide promoted the formation of β-sheet-enriched nanofibres, and this peptide-driven assembly behaviour was retained after bioorthogonal conjugation to the anti-TREM2 antibody. APACs redirected TAMs from lipid-supported oxidative respiration towards glycolysis, enhanced tumour-cell phagocytosis and antigen-specific CD8⁺ T-cell activation, and produced sustained, macrophage-dependent tumour control and reduced pulmonary and hepatic metastatic burden in syngeneic TNBC models. These findings establish a biologically guided supramolecular strategy that integrates TREM2-directed macrophage modulation with PD-1 blockade to coordinate innate and adaptive antitumour immunity within macrophage-rich TNBC niches.
- Open Access
- 6 July 2024
- Published by Springer Nature in Nature Communications
- Vol. 15 (1) , 1-19
An in-situ peptide-antibody self-assembly to block CD47 and CD24 signaling enhances macrophage-mediated phagocytosis and anti-tumor immune responses
Targeted immunomodulation for reactivating innate cells, especially macrophages, holds great promise to complement current adaptive immunotherapy. Nevertheless, there is still a lack of high-performance therapeutics for blocking macrophage phagocytosis checkpoint inhibitors in solid tumors. Herein, a peptide-antibody combo-supramolecular in situ assembled CD47 and CD24 bi-target inhibitor (PAC-SABI) is described, which undergoes biomimetic surface propagation on cancer cell membranes through ligand-receptor binding and enzyme-triggered reactions. By simultaneously blocking CD47 and CD24 signaling, PAC-SABI enhances the phagocytic ability of macrophages in vitro and in vivo, promoting anti-tumor responses in breast and pancreatic cancer mouse models. Moreover, building on the foundation of PAC-SABI-induced macrophage repolarization and increased CD8+ T cell tumor infiltration, sequential anti-PD-1 therapy further suppresses 4T1 tumor progression, prolonging survival rate. The in vivo construction of PAC-SABI-based nano-architectonics provides an efficient platform for bridging innate and adaptive immunity to maximize therapeutic potency.
- 6 July 2024
- Published by Springer Nature in Nature Communications
- Vol. 15 (1) , 1-19
Open AccessAn in-situ peptide-antibody self-assembly to block CD47 and CD24 signaling enhances macrophage-mediated phagocytosis and anti-tumor immune responses
Targeted immunomodulation for reactivating innate cells, especially macrophages, holds great promise to complement current adaptive immunotherapy. Nevertheless, there is still a lack of high-performance therapeutics for blocking macrophage phagocytosis checkpoint inhibitors in solid tumors. Herein, a peptide-antibody combo-supramolecular in situ assembled CD47 and CD24 bi-target inhibitor (PAC-SABI) is described, which undergoes biomimetic surface propagation on cancer cell membranes through ligand-receptor binding and enzyme-triggered reactions. By simultaneously blocking CD47 and CD24 signaling, PAC-SABI enhances the phagocytic ability of macrophages in vitro and in vivo, promoting anti-tumor responses in breast and pancreatic cancer mouse models. Moreover, building on the foundation of PAC-SABI-induced macrophage repolarization and increased CD8+ T cell tumor infiltration, sequential anti-PD-1 therapy further suppresses 4T1 tumor progression, prolonging survival rate. The in vivo construction of PAC-SABI-based nano-architectonics provides an efficient platform for bridging innate and adaptive immunity to maximize therapeutic potency.